Whitehawk Therapeutics sharpens HWK-016 case as MUC16 emerges as a stronger ADC target in gynecologic cancers
Whitehawk Therapeutics says new MUC16 data support HWK-016 in gynecologic cancers. Read what this could change for ADC development.
Pharma & Biotech
Pharma & Biotech
Why Pendulum Therapeutics is taking its microbiome platform beyond metabolic health with Mayo Clinic
Pendulum Therapeutics has expanded its Mayo Clinic collaboration into women’s health and dermatology. Read what this could mean for microbiome medicine.
Medical Devices & Diagnostics
Why Miracell’s SMART M-CELL FDA clearance could reshape the PRP and BMAC device market
Miracell has won FDA 510(k) clearance for SMART M-CELL. Read what it changes for PRP, BMAC, adoption, and regenerative medicine competition.
Pharma & Biotech
Can Apotex crack the complex generic code for semaglutide before the glucagon-like peptide-1 market resets?
Apotex won first tentative U.S. approval for generic semaglutide. Read what it could mean for glucagon-like peptide-1 access, pricing, and competition.
Pharma & Biotech
Can IASO Bio and Instituto Butantan make CAR-T therapy affordable for Brazil’s public health system?
IASO Bio and Instituto Butantan are betting on local CAR-T development in Brazil. Find out what this could change for access, cost, and cancer care.
Pharma & Biotech
What to watch as IDEAYA Biosciences reports OptimUM-02 topline results in uveal melanoma
IDEAYA Biosciences will report OptimUM-02 topline data on April 13. Read why this uveal melanoma trial could shift the treatment landscape.
Pharma & Biotech
CUC America expands MSK embolization strategy with Dr. Yuji Okuno and Dr. Osman Ahmed collaborations
CUC America is expanding MSK embolization through office-based labs. Read what this means for genicular artery embolization adoption and pain care scale-up.
Pharma & Biotech
Can Lupin Limited gain ground in cardiometabolic generics with United States dapagliflozin launch?
Lupin Limited has launched generic dapagliflozin in the United States. Read what it means for Farxiga, pricing pressure, and market access.
Pharma & Biotech
What Verrica Pharmaceuticals’ VP-315 data may reveal about the future of skin cancer immunotherapy
Read how Verrica Pharmaceuticals’ VP-315 data could reshape skin cancer immunotherapy and what clinicians and investors should watch next.
Pharma & Biotech
How Telix Pharmaceuticals Limited may be building a stronger neuro-oncology diagnostics franchise
Telix Pharmaceuticals Limited’s TLX101-Px NDA has been accepted by the FDA. Discover what this means for glioma imaging and the September decision.